What can economics add to health technology assessment? Please not just another cost-effectiveness analysis!
Evidence based medicine is not only important for clinical practice, but national governments have embraced it through health technology assessment (HTA). HTA combines data from randomized controlled trials (RCT) and observational studies with an economic component (among other issues). HTA, however, is not taking full advantage of economics. This paper presents five areas in which economics may improve not only HTA, but the RCT methods that underpin it. HTA needs to live up to its original agenda of being a interdisciplinary field and draw methods not just from biostatistics, but from a range of discipline, including economics. By focusing only on cost effectiveness analysis (CEA), however, we go nowhere close to fulfilling this potential.
Group Leader, University of Heidelberg - Medical School, International Health Economics and Outcomes Research, Department of Tropical Hygiene and Public Health, Im Neuenheimer Feld 324, D-69120 Heidelberg, Germany. healtheconomics@hotmail.com.
John Fp
JF
Bridges